Meningococcemia future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Changes made per Mahshid's request) |
||
| (3 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Meningococcemia}} | {{Meningococcemia}} | ||
{{CMG}} ; {{AE}} {{Ammu}} | |||
==Overview== | |||
Future investigational therapies are showing promising results where 2 new vaccines were being developed against serogroup B and 3 new types of antigen have been found to be useful in making vaccines more potent. | |||
==Future Therapies== | |||
*Two vaccines developed to prevent serogroup B vaccine are in late-stage clinical development in the United States. | |||
Two vaccines developed to prevent serogroup B vaccine are in late-stage clinical development in the United States. A multicomponent serogroup B meningococcal vaccine (4CMenB), approved for use in Europe by the European Medicines Agency in January 2013, was developed by sequencing the meningococcal B genome and testing surface antigens for their ability to elicit an immunogenic response. Three novel antigens identified, factor-H binding protein (fHbp), Neisserial adhesion A (NadA), and Neisseria heparin binding antigen (NHBA), were combined with OMV from the New Zealand epidemic strain NZ98/254 | *A multicomponent serogroup B meningococcal vaccine (4CMenB), approved for use in Europe by the European Medicines Agency in January 2013, was developed by sequencing the meningococcal B genome and testing surface antigens for their ability to elicit an immunogenic response. | ||
*Three novel antigens identified, factor-H binding protein (fHbp), Neisserial adhesion A (NadA), and Neisseria heparin binding antigen (NHBA), were combined with OMV from the New Zealand epidemic strain NZ98/254<ref name="pmid22318278">{{cite journal| author=Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S et al.| title=Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. | journal=JAMA | year= 2012 | volume= 307 | issue= 6 | pages= 573-82 | pmid=22318278 | doi=10.1001/jama.2012.85 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22318278 }} </ref>. | |||
Although the signs and symptoms of meningococcal disease are frequently nonspecific, increasing awareness for meningococcal disease can result in earlier medical care-seeking behavior and improved clinical outcomes. In addition, educating adolescents and their parents about the benefits of receiving MenACWY is key to preventing a substantial number of cases of meningococcal disease. Finally, educating policy makers and the general public about the benefits of receiving MenACWY vaccine might improve vaccination coverage rates and substantially decrease the burden of meningococcal disease in the United States. | *The second vaccine, bivalent recombinant lipoprotein 2086 vaccine, contains two families of the same protein, fHbp, as 4CMenB. When these vaccines are licensed, vaccines to prevent all five serogroups that cause most meningococcal disease worldwide will be available for the first time. | ||
*Extensive research is needed to understand better how to conduct optimal implementation of noncapsular based meningococcal vaccines. | |||
*Although the signs and symptoms of meningococcal disease are frequently nonspecific, increasing awareness for meningococcal disease can result in earlier medical care-seeking behavior and improved clinical outcomes. | |||
*In addition, educating adolescents and their parents about the benefits of receiving MenACWY is key to preventing a substantial number of cases of meningococcal disease. Finally, educating policy makers and the general public about the benefits of receiving MenACWY vaccine might improve vaccination coverage rates and substantially decrease the burden of meningococcal disease in the United States. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
Latest revision as of 18:03, 18 September 2017
|
Meningococcemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Meningococcemia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Meningococcemia future or investigational therapies |
|
Meningococcemia future or investigational therapies in the news |
|
Blogs on Meningococcemia future or investigational therapies |
|
Risk calculators and risk factors for Meningococcemia future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Future investigational therapies are showing promising results where 2 new vaccines were being developed against serogroup B and 3 new types of antigen have been found to be useful in making vaccines more potent.
Future Therapies
- Two vaccines developed to prevent serogroup B vaccine are in late-stage clinical development in the United States.
- A multicomponent serogroup B meningococcal vaccine (4CMenB), approved for use in Europe by the European Medicines Agency in January 2013, was developed by sequencing the meningococcal B genome and testing surface antigens for their ability to elicit an immunogenic response.
- Three novel antigens identified, factor-H binding protein (fHbp), Neisserial adhesion A (NadA), and Neisseria heparin binding antigen (NHBA), were combined with OMV from the New Zealand epidemic strain NZ98/254[1].
- The second vaccine, bivalent recombinant lipoprotein 2086 vaccine, contains two families of the same protein, fHbp, as 4CMenB. When these vaccines are licensed, vaccines to prevent all five serogroups that cause most meningococcal disease worldwide will be available for the first time.
- Extensive research is needed to understand better how to conduct optimal implementation of noncapsular based meningococcal vaccines.
- Although the signs and symptoms of meningococcal disease are frequently nonspecific, increasing awareness for meningococcal disease can result in earlier medical care-seeking behavior and improved clinical outcomes.
- In addition, educating adolescents and their parents about the benefits of receiving MenACWY is key to preventing a substantial number of cases of meningococcal disease. Finally, educating policy makers and the general public about the benefits of receiving MenACWY vaccine might improve vaccination coverage rates and substantially decrease the burden of meningococcal disease in the United States.
References
- ↑ Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S; et al. (2012). "Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial". JAMA. 307 (6): 573–82. doi:10.1001/jama.2012.85. PMID 22318278.